Disease · EFO_0009706
latent autoimmune diabetes in adults
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. latent autoimmune diabetes in adults. Diseases, record EFO_0009706. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009706
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- latent autoimmune diabetes in adults
- Open Targets ID
- EFO_0009706
- Other names
- LADA
- Highest stage of its drugs
- Phase 2, for 4 of its 13 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs13
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DIAPEP-277 | CHEMBL4297934 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| ERGOCALCIFEROL | CHEMBL1536 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GLUTAMATE DECARBOXYLASE 2 | CHEMBL4594599 | Enzyme | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GLUTAMIC ACID | CHEMBL575060 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN HUMAN | CHEMBL1201631 | Protein | Phase 1/2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| SITAGLIPTIN | CHEMBL1422 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LIRAGLUTIDE | CHEMBL4084119 | Protein | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METFORMIN | CHEMBL1431 | Small molecule | Unknown | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CHOLECALCIFEROL | CHEMBL1042 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| COFROGLIPTIN | CHEMBL4646510 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 13
See all 13 drugsTargets57
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| INSR | Insulin receptor | 2 | Insulin receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/3643 | Drugs and targets |
| VDR | Vitamin D3 receptor | 2 | Vitamin D receptor agonist | Phase 2 | https://conductscience.org/library/genes/7421 | Drugs and targets |
| ABCC8 | Sulfonylurea receptor 1, Kir6.2 | 1 | Sulfonylurea receptor 1, Kir6.2 blocker | Unknown | https://conductscience.org/library/genes/6833 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Unknown | https://conductscience.org/library/genes/4697 | Drugs and targets |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Unknown | https://conductscience.org/library/genes/56901 | Drugs and targets |
| DPP4 | Dipeptidyl peptidase 4 | 1 | Dipeptidyl peptidase IV inhibitor | Phase 1/2 | https://conductscience.org/library/genes/1803 | Drugs and targets |
| GLP1R | Glucagon-like peptide 1 receptor | 1 | Glucagon-like peptide 1 receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/2740 | Drugs and targets |
| GPD2 | Glycerol-3-phosphate dehydrogenase, mitochondrial | 1 | Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor | Unknown | https://conductscience.org/library/genes/2820 | Drugs and targets |
| KCNJ11 | Sulfonylurea receptor 1, Kir6.2 | 1 | Sulfonylurea receptor 1, Kir6.2 blocker | Unknown | https://conductscience.org/library/genes/3767 | Drugs and targets |
| MT-ND1 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Unknown | https://conductscience.org/library/genes/4535 | Drugs and targets |
1 to 10 of 57
See all 57 targetsTrials9
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04262479 | Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes | Phase 2 | 14 | 2025-06-08 | Latent Autoimmune Diabetes in Adults | ERGOCALCIFEROL, GLUTAMIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT00776607 | Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA) | Not applicable | 200 | Latent Autoimmune Diabetes in Adults LADA | GLITAZONE, INSULIN HUMAN, METFORMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00456027 | Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult) | Phase 2 | 160 | Latent Autoimmune Diabetes in Adult (LADA) | GLUTAMATE DECARBOXYLASE 2 | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00058981 | Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA) | Phase 2 | 100 | Diabetes, Autoimmune | DIAPEP-277 | Its record names the disease | ClinicalTrials.gov | |
| NCT07460336 | Effects of Cofrogliptin on Beta-Cell Function in LADA Patients | Not applicable | 84 | Latent Autoimmune Diabetes in Adults (LADA) | CHOLECALCIFEROL, COFROGLIPTIN, METFORMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01140438 | Treatment of Latent Autoimmune Diabetes of the Adult | Not applicable | 64 | Diabetes | INSULIN HUMAN, METFORMIN, REPAGLINIDE, SITAGLIPTIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00232375 | Intervention to Preserve Beta-Cell Function in GAD Ab-Positive Diabetes | Not applicable | 42 | GAD Ab Positive Clinically Type 2 Diabetic Patients | INSULIN HUMAN | Its record names the disease | ClinicalTrials.gov | |
| NCT03011021 | Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes | Phase 1/2 | 40 | Type1 Diabetes Mellitus, Autoimmune Diabetes | INSULIN HUMAN, LIRAGLUTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01159847 | Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA) | Phase 1/2 | 30 | Type 1 Diabetes | INSULIN HUMAN, SITAGLIPTIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0009706
GET https://conductscience.org/api/diseases/v1/EFO_0009706/targets?page=2